Mentalization Orientated Psychoeducation Group for Adult ADHD (MOPAD)

NCT07928440, Not applicable, Not yet recruiting, Surrey and Borders Partnership NHS Foundation Trust

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Field	Value	Source
Title	Mentalization Orientated Psychoeducation Group for Adult ADHD (MOPAD)	ClinicalTrials.gov
NCT number	NCT07928440	ClinicalTrials.gov
Status	Not yet recruiting	ClinicalTrials.gov
Phases	Not applicable	ClinicalTrials.gov
Enrollment	16 participants, estimated	ClinicalTrials.gov
Lead sponsor	Surrey and Borders Partnership NHS Foundation Trust	ClinicalTrials.gov
Conditions	ADHD - Attention Deficit Disorder With Hyperactivity	ClinicalTrials.gov
Interventions	The MOPAD study tests whether an introductory Mentalization-Based Treatment (iMBT)	ClinicalTrials.gov
First posted	2026-11-10	ClinicalTrials.gov
Last updated	2026-11-10	ClinicalTrials.gov

Registered outcomes 18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description	Source
Primary	This study will examine the feasibility of delivering 12 weekly sessions (90minutes/session plus 10/15 min break in between) of iMBT in a group format to adults with ADHD.	20 months	Recruitment rate : The percentage of participants recruited in the study. It will be considered feasible if 11 out of 16 patients were recruited for the intervention.	ClinicalTrials.gov
Primary	This study will examine the feasibility of delivering 12 weekly sessions (90minutes/session plus 10/15 min break in between) of iMBT in a group format to adults with ADHD.	20 months	Attrition rate : The percentage of participants retained in the study. It will be considered feasible if 70% were retained by the end of intervention.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	ASRS V1.1 (Adult ADHD self-report scale) : * What it measures: Symptom frequency and presentation of adult ADHD over the prior 6 months, directly mapped to diagnostic criteria. * Score Range: Consists of 18 items split into Part A (6 core screening items) and Part B (12 tracking items). Items use a 5-point frequency scale (0 = Never to 4 = Very Often), yielding a total raw score range of 0 to 72. * Interpretation: Part A is the primary screening mechanism. If an individual marks 4 or more responses within the darkly shaded boxes in Part A, it indicates a high likelihood of ADHD and warrants a formal clinical evaluation. Part B tracks broader symptom severity across domains without a strict diagnostic cutoff.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	CAARS-2 (Conners Adult ADHD Rating scale) * What it measures: Core ADHD symptoms and associated clinical impairments (such as emotional dysregulation and negative self-concept) in adults aged 18 and older. * Score Range: Raw scores from self and observer reports are converted into standardized T-scores, which typically range from below 30 to over 90. It also generates a dedicated ADHD Index probability score spanning 1% to 99%. * Interpretation: Standardized T-scores are normalized around a mean of 50. A T-score of 60-64 represents elevated symptoms, while a T-score of 65 or higher is considered clinically significant (highly elevated). For the ADHD Index, a probability score between 90% and 99% indicates a "Very High" likelihood that the profile matches individuals diagnosed with ADHD.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	AAQoL (Adult ADHD Quality of life) * What it measures: The specific impact of ADHD on an individual's health-related quality of life over the past two weeks. It evaluates four distinct domains: Life Productivity, Psychological Health, Life Outlook, and Relationships. * Score Range: 29 items are originally rated on a 1-to-5 Likert scale, which are then reverse-scored and mathematically transformed onto a standardized scale of 0 to 100. * Interpretation: Higher scores indicate a better quality of life and fewer functional impairments. Scores are generally tiered into severity thresholds: * 76-100: Little to no quality-of-life impairment. * 51-75: Mild impairment. * 26-50: Moderate impairment. * 0-25: Severe functional impairment.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	DERS-18 (Difficulties in Emotion regulation 18) * What it measures: Deficits in emotional regulation capacities across six dimensions: emotional non-acceptance, difficulty engaging in goal-directed behaviors, impulse control issues, lack of emotional awareness, limited access to regulation strategies, and lack of emotional clarity. * Score Range: 18 items scored on a 5-point Likert scale (1 = Almost Never to 5 = Almost Always). The total score ranges from 18 to 90. * Interpretation: Higher total and subscale scores indicate greater difficulties with emotion regulation (more severe dysregulation). It is highly useful in tracking treatment progress or evaluating clinical distress underlying internalizing psychopathology.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	UPPS (Impulsive behaviour scale) * What it measures: Five distinct personality pathways that lead to impulsive action: Negative Urgency (acting rashly when distressed), Positive Urgency (acting rashly when overjoyed), Lack of Premeditation (failing to plan ahead), Lack of Perseverance (quitting difficult tasks), and Sensation Seeking. * Score Range: The full questionnaire consists of 59 statements rated from 1 (Agree Strongly) to 4 (Disagree Strongly). Items are averaged per dimension to yield an item mean scoring range from 1 to 4. * Interpretation: Higher item mean scores (closer to 4) represent higher levels of impulsivity along that specific dimension. Because the traits operate independently, an individual can score high on one trait (like Sensation Seeking) and low on another (like Negative Urgency)	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	MENT-S (The mentalization scale) * What it measures: The fundamental capacity to mentalize-meaning the reflective ability to perceive, interpret, and understand your own mental states as well as the mental states of others. It breaks down into Self-Related, Other-Related, and Motivation to Mentalize subscales. * Score Range: 28 items rated on a 5-point Likert scale (1 = Completely Untrue to 5 = Completely True). Total scores range from 28 to 140. * Interpretation: Higher total scores indicate a stronger global mentalization capacity and healthier, more adaptive reflective functioning. Lower scores indicate an impaired capacity to comprehend emotional or cognitive motivations behind human behavior.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	RFQ-8 (Reflective function Questionnaire) * What it measures: Extreme variations in adult mentalizing capabilities, explicitly flagging hypomentalizing (an inability to consider mental states) or hypermentalizing (developing overly complex, inaccurate assumptions about the mind). * Score Range: 8 items rated on a 1-to-7 scale. Using the primary scoring algorithm, items are recoded to center around an optimal middle ground, yielding subscale score ranges (Certainty vs. Uncertainty) from 0 to 3. * Interpretation: * Uncertainty Subscale (RFQ\_U): High scores indicate hypomentalizing, pointing to a concrete lack of knowledge about mental states. * Certainty Subscale (RFQ\_C): Moderate scores indicate healthy, realistic certainty about the mind. Conversely, extreme high scores on this subscale reflect hypermentalizing (assuming absolute, ungrounded insight into what others are thinking)	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	Adverse events (AE) or serious AE during the trial. This will counted in numbers identified through a clear process outlined in protocol.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	Fidelity of delivery : Adherence will be measured through supervision of the sessions and report from supervisors.	ClinicalTrials.gov
Primary	The study also aims to compare pre and post iMBT group clinical outcome data.	20 months	Acceptability of the intervention to participants: through interview of the participants. Will be reported as themes and quotes from participants.	ClinicalTrials.gov
Secondary	Resource outcomes:	20 months	Time taken to recruit participants: Reported in days	ClinicalTrials.gov
Secondary	Resource outcomes:	20 months	Sample size calculation in number	ClinicalTrials.gov
Secondary	Resource outcomes:	20 months	Data collection success (percentage of participants completed the outcome measures)	ClinicalTrials.gov
Secondary	Resource outcomes:	20 months	Initial assessment of the financial resources required to scale the study: reported in number of professionals involved and how much on average they had to offer in hours/week from the onset of recruitment to completion of the trial.	ClinicalTrials.gov
Secondary	Exploratory endpoints/outcomes	20 months	Participants experience of the intervention	ClinicalTrials.gov
Secondary	Exploratory endpoints/outcomes	20 months	Facilitators' and Co-facilitators' experience of the intervention.	ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as	Source

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units	Source

Participant flow 0

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants	Units counted	Source

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events	Source

Adverse event totals 0

The totals the trial posted for each group.

Total	Group	Affected	At risk	Source

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source

Source 5

Field	Value	Source
Release	trials-2026-11-12-0.4.0	ClinicalTrials.gov
Release manifest SHA-256	0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4	ClinicalTrials.gov
Registry capture	2026-11-12	ClinicalTrials.gov
Results copy, AACT	2026-03-23	ClinicalTrials.gov
NIH clinical studies file	2026-11-13	ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)